☆ 4.7 Editorial Material

Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Related references

Note: Only part of the references are listed.

Review Oncology

Inoperable Early-Stage Non-Small-Cell Lung Cancer: Stereotactic Ablative Radiotherapy and Rationale for Systemic Therapy

Megan E. Daly

Summary: Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable, early-stage non-small-cell lung cancer. However, regional and distant failures remain a challenge, especially in larger and more biologically aggressive tumors. Use of cytotoxic chemotherapy is limited in this patient population, prompting the investigation of alternative systemic therapy options with fewer side effects, such as immune checkpoint inhibitors.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Jay M. Lee et al.

Summary: New adjuvant immunotherapy using immune checkpoint inhibitors (ICIs) shows potential advantages in treating resectable NSCLC, including earlier treatment of micrometastatic disease, broad activation of immune response, and guidance for adjuvant therapy.

ANNALS OF THORACIC SURGERY (2022)

Add to Collection

Article Oncology

Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy

Mark C. Korpics et al.

Summary: This study reviewed the clinical outcomes of thoracic SBRT combined with systemic immunotherapy and found that it achieved excellent local control with acceptable toxicity. The results support the safety of established dose-volume constraints for the lung but also highlight the importance of reporting organ-at-risk challenges near the specified limits in the protocol.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

Add to Collection

Article Oncology

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary O'Brien et al.

Summary: This study evaluated the use of Pembrolizumab as adjuvant therapy for completely resected stage IB-IIIA NSCLC. The results showed that Pembrolizumab significantly improved disease-free survival in both the overall population and the PD-L1 TPS of 50% or greater population.

LANCET ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).

Heather A. Wakelee et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis

Sibo Tian et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)

Add to Collection

Article Oncology

Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis

Corey C. Foster et al.

LUNG CANCER (2019)

Add to Collection

Article Oncology

Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer

Gregory M. Videtic et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)

Add to Collection

Review Oncology

Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes

J. Isabelle Choi

TRANSLATIONAL LUNG CANCER RESEARCH (2019)

Add to Collection

Article Oncology

Stereotactic Body Radiation Therapy and the Influence of Chemotherapy on Overall Survival for Large (≥5 Centimeter) Non-Small Cell Lung Cancer

Vivek Verma et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)

Add to Collection

Article Oncology

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

Narek Shaverdian et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

S. J. Antonia et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Meeting Abstract Oncology

Long-term Results of RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer

R. D. Timmerman et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Radiation pneumonitis after stereotactic radiation therapy for lung cancer

Hideomi Yamashita et al.

WORLD JOURNAL OF RADIOLOGY (2014)

Add to Collection

Article Critical Care Medicine

Extracranial stereotactic radioablation - Results of a phase I study in medically inoperable stage I non-small cell lung cancer

R Timmerman et al.

CHEST (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.